Is blood-brain barrier disruption in humans independently associated with increased matrix metalloproteinase-9?
Baseline MMP-9 was a significant predictor of HARM at 24-hour follow-up, supporting the hypothesis that MMP-9 is associated with BBB disruption. If the association between MMP-9 and BBB disruption is confirmed in future studies, HARM may be a useful imaging marker to evaluate MMP-9 inhibition in ischemic stroke and other populations with BBB disruption.
The site of absorption into the intestine modulates the bioavailability of diltiazem and its two active metabolites.